Metabolic medications work by mimicking natural gut hormones and brain signals, not just by slowing down the digestive tract.

Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down the rapidly evolving landscape of metabolic therapies. From oral options to high-dose formulations and pipeline molecules, the conversation cuts through public confusion to focus on biological mechanisms.

The discussion explores how these therapies interact with complex melanocortin and hormonal pathways in the brain. Rather than relying on rigid protocols or escalating doses prematurely, effective metabolic care focuses on individual biological response and measurable health parameters.

Key Takeaways

• Modern metabolic therapies are designed to mimic native hormones like GLP-1, GIP, and amylin rather than simply slowing gastric emptying.

• Clinical trial dosing sequences are designed for regulatory approval, while individualized clinical practice prioritizes symptom stability and health markers over reaching maximum doses.

• Health improvements such as blood pressure regulation, cholesterol shifts, and liver markers often occur independently of scale changes.

Resources Mentioned

Diabesity Institute Foundations Course

Cooper Center for Metabolism

Connect with Us

Podcast Home:fatsciencepodcast.com

Cooper Center for Metabolism:coopermetabolic.com

Diabesity Institute: diabesityinstitute.org

Resources from Dr. Cooper:coopermetabolic.com/resources

Join Our Community:patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Produced by: Podcast Impact Studio https://podcastimpactstudio.com

Wondering why weight stalls on treatment? Dr. Emily Cooper explains how the brain defends set points and why eating less stops progress.

Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener letters from around the world. The conversation addresses why athletic men with a BMI of 27 can still show high visceral fat on a DEXA scan, how medications defend metabolic set points, and why intentional undereating triggers starvation responses.

The team also examines global access to metabolic treatments, dual incretin agonists versus single agonists, artificial sweeteners, and how to interpret two-hour insulin and glucose tolerance curves.

Key Takeaways

• Rapid weight reduction without adequate nutrition can cause lean mass loss and trigger metabolic defense mechanisms.
• Dual incretin therapies stimulate GIP receptors far more than GLP-1 receptors compared to natural human hormones, creating different patient responses.
• Intentional calorie restriction reduces natural incretin production and can impair metabolic signaling, making mechanical fueling essential.
• Fasting insulin suppression combined with pre-diabetes indicators can reflect the brain pulling glucose during periods of low carbohydrate intake.

Resources Mentioned

Diabesity Foundations Course

Cooper Center for Metabolism

Diabesity Institute

Connect with Us

Podcast Home:fatsciencepodcast.com

Cooper Center for Metabolism:coopermetabolic.com

Diabesity Institute: diabesityinstitute.org

Resources from Dr. Cooper:coopermetabolic.com/resources

Join Our Community:patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Produced by: Podcast Impact Studio https://podcastimpactstudio.com

What do new drug reports really mean for your treatment?

Explore groundbreaking updates on potential diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly. Dr. Emily Cooper dives into top-line results, explaining what these findings mean for those struggling with metabolic issues.

KEY TAKEAWAYS

• Understanding the difference between efficacy estimand and treatment policy estimand.

• Cagrisema’s potential in aiding weight loss compared to Mounjaro in patients with type 2 diabetes.

• Semaglutide's effectiveness in children and its implications.

NOTABLE QUOTE

"Many of our patients with metabolic dysfunction have increased cardiometabolic risk." — Dr. Emily Cooper

LINKS & RESOURCES

Learn more about Diabesity Foundations: learn.diabesityinstitute.org

Podcast Home: fatsciencepodcast.com

Cooper Center for Metabolism: coopermetabolic.com

Diabesity Institute: diabesityinstitute.org

Resources from Dr. Cooper: coopermetabolic.com/resources

Join Our Community: patreon.com/cw/FatSciencePodcast

Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com

Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.

This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.